3E Bioventures Capital: A healthcare-focused venture fund investing in drugs, devices, diagnostics, and IT services.
2015
3E Bioventures Capital is a life science-focused venture fund investing in global health innovators. The firm concentrates on biotech, including new drugs, modalities, and drug discovery platforms, as well as TechBio, the intersection of biology and technology. Their investments span various stages, with a particular emphasis on Series A and B rounds.
The firm adopts a science-driven, entrepreneur-friendly investment philosophy, working closely with companies and research institutions. Notable portfolio companies include Ansun Biopharma, Dewpoint Therapeutics, and Cullgen. 3E Bioventures Capital offers expertise, efficiency, and execution to support their investments in transformative healthcare solutions.
3E Bioventures Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies14
Follow-on Investments5
Current Portfolio Count14
Top Investment Stages
Series A8 (42.1%)
Series B8 (42.1%)
Series C3 (15.8%)
Stage Mix
Series A 42%Series B 42%Series C 16%
Concentration shown as share of disclosed investments by stage.
